2 Via matching analysis among male and female patients with hormone receptor-positive breast cancer, we demonstrated clearly that the benefit of TAM These included the approaches to the use of endocrine therapy in the
, Altmann, U
Background Most breast cancers (BCs) in men are hormone receptor–positive
There are three main ways that hormone therapy is used to treat hormone
Conclusions Few studies specifically report data on adherence to and toxicities from
But if you look at the patients with endocrine therapy– sensitive breast
Where clinical guidance is provided in this topic, the anatomic staging system set forth in the eighth edition of the American Joint Committee on Cancer Staging Manual is used This review will revise all available data that could improve the treatment of MaBC, with a special focus on adjuvant systemic treatments
, Smith B
Question How do estradiol levels in male patients with hormone receptor–positive breast cancer change after 3 months of therapy with aromatase inhibitor (AI) plus gonadotropin-releasing hormone analogue (GnRHa) compared with GnRHa plus tamoxifen or tamoxifen alone?
doi: 10
included adult women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer Adjuvant endocrine therapy is the principal systemic treatment for non-metastatic hormone receptor-positive breast cancer
CrossRef View in Scopus Google Scholar
Prior small, single-institution studies have suggested that men may have high rates of discontinuing adjuvant endocrine treatment
It should be noted that evidence suggests that patients with estrogen receptor-positive tumors are more likely to benefit from tamoxifen
Tamoxifen is the preferred endocrine agent of choice in adjuvant treatment of estrogen receptor-positive male breast cancer
2, 3 Although clinical trials have clearly demonstrated the benefits of adjuvant tamoxifen in women with breast cancer, little is known about how this drug is actually used in the general
Giordano, MD, MPH 2,3 BACKGROUND: Most breast cancers (BCs) in men are hormone receptor–
In women at high risk of breast cancer, tamoxifen can be used to help lower the risk of developing breast cancer
Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen
5%) and distant